Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania
Status:
Completed
Trial end date:
2020-02-01
Target enrollment:
Participant gender:
Summary
Sulfadoxine-pyrimethamine (SP) is currently recommended by the World Health Organization for
use as intermittent preventive treatment against malaria in pregnancy (IPTp) in areas of
moderate to high malaria transmission. However, in some locales malaria parasites have lost
sensitivity to SP, compromising its protective effect. Dihydroartemisinin-piperaquine (DP) is
a candidate replacement for SP. This trial is designed to confirm the cardio-safety of DP
compared to SP amongst pregnant women in Tanzania.
Phase:
Phase 2
Details
Lead Sponsor:
London School of Hygiene and Tropical Medicine
Collaborators:
Kilimanjaro Christian Medical Centre, Tanzania National Institute for Medical Research, Tanzania
Treatments:
Artemisinins Artenimol Dihydroartemisinin Fanasil, pyrimethamine drug combination Piperaquine Pyrimethamine Sulfadoxine